Loading
A phase 1/2 trial of Vepdegestrant and Atirmociclib in advanced solid tumours, run by Pfizer, active and no longer recruiting.
A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer. is a phase 1/2 interventional study registered as NCT06206837 by Pfizer, with 71 participants enrolled, started 2024-02-19 and due to reach its primary completion in 2025-09-05. Interventions recorded: vepdegestrant and PF-07220060.
Shares Vepdegestrant, CDK4/6 inhibitors, PROTACs & molecular glues (targeted protein degradation), Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Vepdegestrant, CDK4/6 inhibitors, PROTACs & molecular glues (targeted protein degradation), Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Vepdegestrant, CDK4/6 inhibitors, PROTACs & molecular glues (targeted protein degradation), Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Vepdegestrant, PROTACs & molecular glues (targeted protein degradation), Endocrine therapy (SERMs, AIs, SERDs), Pfizer (incl. Seagen) and the tag pipeline.
Shares Atirmociclib, CDK4/6 inhibitors, Pfizer (incl. Seagen), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Atirmociclib, CDK4/6 inhibitors, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Atirmociclib, CDK4/6 inhibitors, Pfizer (incl. Seagen) and the tag pipeline.
Shares CDK4/6 inhibitors, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.